Technology ID

Methods of Inducing Immune Tolerance Using Immunotoxins

Linked ID
David Neville (NIMH)
Francis Thomas (University of Alabama @ Birmingham)
Judith Thomas (University of Alabama @ Birmingham)
Lead Inventors
David Neville (NIMH)
Francis Thomas (University of Alabama @ Birmingham)
Judith Thomas (University of Alabama @ Birmingham)
Therapeutic Areas
Commercial Applications
  • Use of immunotoxins decreases T cell population, allowing greater host immune tolerance of transplants and grafts.
  • Specific method for increasing immune tolerance to pancreatic islet transplants.
This abstract was migrated from the abstract field for the ITS record for Serial No. 09/064,413. It would not have been published in the Federal Register. Author and date written are unknown. The 09/064,413 patent application discloses a method for treating diabetics by administering an immunotoxin, thereby reducing the patient's T-Cell population, and by adminstering pancreatic islet cells from a donor. The method described is effective for treating Type I or Type II diabetes. More specifically, the invention relates to techniques for inducing immune tolerance inducing techniques with pancreatic islet transplantation, for the purpose of inhibiting rejection of the transplant. The invention provides a short course immune tolerance inducing treatment regime utilizing an anti-CD3 immunotoxin that, optionally with adjunct immunosuppresive agents, prevents pancreatic islet cell rejection while maintaining long term islet cell function following pancreatic islet cell transplantation. The invention further provides sufficient immune tolerance to pancreatic islet transplantation so that xenogeneic transplants are not rejected. Thus, the method of the invention provides a means for treating diabetes, wherein the need for exogenous insulin or immunosuppressive agents is eliminated. A method of inducing immune tolerance using an immunotoxin for xenogeneic or allogeneic pancreatic islet cell transplantation is provided. Also, provided is a method of inhibiting a rejection response of a transplant recipient, comprising administering an immunotoxin during the peritransplant period, thereby transiently reducing the number of T-Cell lymphocytes and promoting long-term survival of the transplant.
Competitive Advantages
  • Specificity of the immunotoxin avoids the killing of other cells, reducing side-effects associated with other mechanisms of treatment (X-ray and cyclophosphamide) such as infection and induced malignancy.
  • A GMP production process for the immunotoxin has already been successfully implemented.

Request More Info

Licensing Contact